Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - chlorhexidine acetate, quantity: 5 mg/ml - solution, irrigation - excipient ingredients: cetrimide; glacial acetic acid; water for injections; methylene blue - chlorhexidine acetate (0.5 %) antiseptic solution is used as a general antiseptic. it is used for the cleaning and disinfecting of wounds and the antiseptic treatment of burns.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - chlorhexidine acetate, quantity: 1 mg/ml - solution, irrigation - excipient ingredients: water for injections; glacial acetic acid; methylene blue - chlorhexidine acetate (0.1 %) antiseptic solution is used as a general antiseptic. it is used for the cleaning and disinfecting of wounds and the antiseptic treatment of burns.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - chlorhexidine acetate, quantity: 0.5 mg/ml - solution, irrigation - excipient ingredients: glacial acetic acid; methylene blue; water for injections - chlorhexidine acetate (0.5 %) antiseptic solution is used as a general antiseptic. it is used for the cleaning and disinfecting of wounds and the antiseptic treatment of burns.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - bortezomib, quantity: 3.5 mg - injection, powder for - excipient ingredients: mannitol; nitrogen - bortezomib baxter, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,bortezomib baxter, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,bortezomib baxter is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.,bortezomib baxter in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Austraalia - inglise - APVMA (Australian Pesticides and Veterinary Medicines Authority)

baxter laboratories pty ltd - n-octyl bicycloheptene dicarboximide; di-n-propyl isocinchomeronate; diethyltoluamide - lotion - n-octyl bicycloheptene dicarboximide bicyclo active 20.0 mg/g; di-n-propyl isocinchomeronate benzene active 15.0 mg/g; diethyltoluamide insect repellent active 40.0 mg/g - household insecticide - pest control - personal use - fly | mosquito | adult mosquitoes

Austraalia - inglise - APVMA (Australian Pesticides and Veterinary Medicines Authority)

baxter laboratories pty ltd - n-octyl bicycloheptene dicarboximide; di-n-propyl isocinchomeronate; diethyltoluamide - lotion - n-octyl bicycloheptene dicarboximide bicyclo active 20.0 mg/g; di-n-propyl isocinchomeronate benzene active 15.0 mg/g; diethyltoluamide insect repellent active 40.0 mg/g - household insecticide - pest control - personal use - insect

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - furosemide, quantity: 50 mg - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide; sodium chloride - oedema: furosemide-baxter injection is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. furosemide-baxter injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by the intravenous route. parenteral use should be replaced with oral frusemide as soon as practical.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - furosemide, quantity: 20 mg - injection, solution - excipient ingredients: sodium hydroxide; water for injections; sodium chloride; hydrochloric acid - oedema: furosemide-baxter injection is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. furosemide-baxter injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by the intravenous route. parenteral use should be replaced with oral frusemide as soon as practical.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - potassium chloride, quantity: 400 mg/l; sodium lactate, quantity: 3.22 g/l; calcium chloride dihydrate, quantity: 270 mg/l; sodium chloride, quantity: 6 g/l - injection, solution - excipient ingredients: sodium hydroxide; lactic acid; water for injections - is indicated as a source of water and electrolytes. it is also used in patients as a source of bicarbonate in the treatment of mild to moderate metabolic acidosis associated with dehydration or associated with potassium deficiency. these solutions are indicated as methods of intravenous drug delivery, if the drugs are comparable with the solutions. this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium chloride, quantity: 6 g/l; sodium lactate, quantity: 3.22 g/l; potassium chloride, quantity: 2.2 g/l; calcium chloride dihydrate, quantity: 270 mg/l - injection, solution - excipient ingredients: lactic acid; sodium hydroxide; water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)